• Teva Announces FDA Approval of QVAR RediHaler americanpharmaceuticalreview
    August 11, 2017
    Teva Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has approved QVAR RediHaler inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
PharmaSources Customer Service